Purpose: The aim of this study was to compare the intraocular pressure (IOP)-lowering effect of latanoprost and travoprost as primary therapy in patients with chronic angle-closure glaucoma (CACG) after peripheral iridotomy. Methods: Seventy-three (73) CACG patients with IOP > 19 mmHg after peripheral iridotomy and without previous antiglaucoma medication were consecutively recruited. CACG was defined as the presence of chronically elevated IOP, glaucomatous optic neuropathy, and a corresponding visual field defect in eyes with occludable angle and peripheral anterior synechiae on gonioscopy. Patients were randomly assigned to 2 groups, based on daily treatment with either latanoprost 0.005% or travoprost 0.004% in the evening for 12 weeks. The IOP was measured at 9 AM and 4 PM at baseline and at 4, 8, and 12 weeks. Between-group differences in mean diurnal IOP and IOP reduction were analyzed. Results: After 12 weeks of treatment, mean IOP for both the latanoprost and travoprost groups was significantly reduced, when compared to the baseline IOP (from 21.3 ± 1.8 mmHg to 16.0 ± 2.3 mmHg and 21.7 ± 1.7 to 16.7 ± 2.2 mmHg; P < 0.001 for both). There was no significant difference in IOP reduction between the 2 treatment groups (P = 0.19). At 4 and 8 weeks, the IOP changes from the baseline were statistically significant at all time points for both drugs (all P < 0.001). Conclusions: Both latanoprost and travoprost significantly reduced IOP in our sample of CACG patients after peripheral iridotomy.
ASJC Scopus subject areas
- Pharmacology (medical)